title: Drug discovery based on genetic and metabolic findings in schizophrenia.
abstract: Recent progress in the genetics of schizophrenia provides the rationale for re-evaluating causative factors and therapeutic strategies for this disease. Here, we review the major candidate susceptibility genes and relate the aberrant function of these genes to defective regulation of energy metabolism in the schizophrenic brain. Disturbances in energy metabolism potentially lead to neurodevelopmental deficits, impaired function of the mature nervous system and failure to maintain neurites/dendrites and synaptic connections. Current antipsychotic drugs do not specifically address these underlying deficits; therefore, a new generation of more effective medications is urgently needed. Novel targets for future drug discovery are identified in this review. The coordinated application of structure-based drug design, systems biology and research on model organisms may greatly facilitate the search for next-generation antipsychotic drugs.
authors.affiliation: Professor and Director of Basic Research, Departments of Psychiatry and Pharmacology, Louisiana State University Health Sciences Center, Shreveport, LA 71130, USA. ddwyer@lsuhsc.edu.
authors.forename: Donard S
authors.initials: DS
authors.lastname: Dwyer
authors.forename: Kathrine
authors.initials: K
authors.lastname: Weeks
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Aamodt